RINGPU(300119) Southwest Securities·2024-11-06 16:50Investment Rating - The report maintains a "Buy" rating for the company with a target price of 21.50 CNY over the next six months [1][3][11]. Core Insights - The company reported a stable revenue growth of 10.06% year-on-year for the first three quarters of 2024, achieving a revenue of 1.747 billion CNY. However, the net profit attributable to the parent company decreased by 10.58% year-on-year to 245 million CNY, indicating challenges such as increased market competition and rising costs [1][2]. - The company is actively exploring new markets, particularly in the pet healthcare sector, which has shown significant growth potential. The launch of the cat trivalent vaccine has been successful, with sales exceeding one million doses [2][3]. Summary by Sections Financial Performance - For Q3 2024, the company achieved a revenue of 648 million CNY, a year-on-year increase of 9.22%, while the net profit attributable to the parent company was 86 million CNY, down 10.3% year-on-year [1]. - The company’s revenue for 2024 is projected to reach approximately 2.249 billion CNY, with a growth rate of 10.70% expected in 2025 [4][8]. Research and Development - The company has increased its R&D investment, with R&D expenses reaching 51.68 million CNY in Q3 2024, representing a rate of 7.98% of revenue. This investment supports the development of new products, including vaccines and enzyme preparations [2][3]. Market Position and Strategy - The company has established a strong market presence in the animal healthcare industry and is expanding its pet product offerings. The integration of various sales channels, including partnerships with pet hospitals, is expected to enhance sales growth [2][3]. - The pet healthcare segment is identified as a blue ocean market with significant growth potential, supported by the successful launch of new products and an expanding distribution network [2][3]. Earnings Forecast - The projected earnings per share (EPS) for 2024, 2025, and 2026 are 0.70 CNY, 0.86 CNY, and 1.05 CNY, respectively, with corresponding dynamic price-to-earnings (PE) ratios of 24, 20, and 16 [3][4][11].